Pfizer (PFE) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Pfizer stock price, PFE
Pfizer stock chart:
Pfizer close price: 33.01
Stock price forecast:
UP TO +0.58%
Total forecasts: 89
Reached: 13 (14.61%)
Total Win: 4.57 (13.56%)
Showing 1-10 of 643 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Pfizer latest news:
Adviser charged with insider trading on Pfizer-King deal pleads guilty
NEW YORK, July 25 (Reuters) - A Long Island, New York,
investment adviser accused of engaging in insider trading after
being tipped off about Pfizer Inc's $3.6 billion
acquisition of King Pharmaceuticals Inc pleaded guilty on
Tuesday, federal prosecutors said.
Pfizer receives token payment to exit Brazil venture, sources say
SAO PAULO (Reuters) - Pfizer Inc has agreed to exit Laboratório Teuto Brasileiro SA for a token amount after failing to find a buyer for the 40 percent stake it held in the Brazilian generic drugmaking joint venture, two people with knowledge of the matter said on Tuesday.
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
Exelixis Inc EXEL announced results from an analysis of the data from the phase II trial CABOSUN The study compared Cabometyx to Pfizer s PFE Sutent in the first line treatment of intermediate or poor risk advanced renal cell carcinoma RCC patients We note that Cabometyx tablets
BRIEF-Pfizer to have exclusive rights to distribute, commercialize CRESEMBA in Europe
* Pfizer receives exclusive commercialization rights in
Europe for CRESEMBA, a novel treatment for potentially
life-threatening fungal infections among immunocompromised
Most Dow stocks are below their 50-day moving averages
As the Dow Jones Industrial Average slips Wednesday below its 50-day moving average (MA), which many technicians use to define the short-term trend, 17 of its 30 components are also below their respective 50-day MAs. Of that total, shares of Boeing Co. and Merck & Co. Inc. are below their 50-day MAs after closing above them on Tuesday, while UnitedHealth Group Inc.'s stock was above its 50-day MA as recently as Monday. Of that total, Pfizer Inc. , Chevron Corp. , General Electric Co. , Intel Corp. , Verizon Communications Inc. , International Business Machines Corp. , Merck and Procter & Gamble Co. were also below their respective 200-day MAs, which are viewed as dividing lines between longer-term uptrends and downtrends. Exxon Mobil Corp.'s stock was below its 200-day MA, but was still above its 50-day MA. The Dow was down 237 points at 20743, below the 50-day MA at 20,783, but well above the 200-day MA at 19,547.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Sangamo shares jump on Pfizer collaboration, quarterly results
Sangamo Therapeutics Inc. shares surged after the gene therapy company reported a narrower-than-expected loss for the quarter and a collaboration with pharmaceutical giant Pfizer Inc. . Sangamo shares jumped 42% to $6.15 after hours. The company reported a first-quarter loss of 23 cents a share on revenue of $3.4 million. Analysts surveyed by FactSet had estimated a loss of 28 cents a share on revenue of $4 million. Separately, Sangamo said it will receive a $70 million upfront payment from Pfizer for a development and manufacturing collaboration for a hemophilia A treatment. Sangamo said it was eligible for up to $450 million in milestone payments under the deal.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Pfizer says multi-year extension of collaboration with Bill & Melinda Gates Foundation, Children's Investment Fund Foundation
* Co, the Bill & Melinda Gates Foundation, Children's
Investment Fund Foundation announced multi-year extension of
Pfizer beats 1Q profit forecasts, but sales slip
Pfizer beat Wall Street's expectations for first-quarter profit, thanks to reduced spending on operations and legal and other costs, along with strong sales of key new drugs and longtime blockbuster pain treatment Lyrica
Prescription for growth at Pfizer? Analysts say deals
(Reuters) - Pfizer Inc posted basically flat first-quarter earnings, prompting suggestions that the largest U.S. drugmaker needs to do deals in order to improve its growth prospects.
Philip Morris International IncPM
Philippine Long Distance Telephone CompanyPHI
Phillips 66 Partners LPPSXP
Phoenix New Media LimitedFENG
Physicians Realty TrustDOC